A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal

Business Insider | 4/9/2018 | Alex Morrell
urbanagirl3 (Posted by) Level 3
Click For Photo: https://amp.businessinsider.com/images/5acbb7754d03869a018b4d72-750-375.jpg

Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal.

The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal.

Dyal - Co-chairman - Investment - Banking - Goldman

Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A deals in Europe.

He's leveraged that experience to land advisory roles with multinational companies since starting his own firm.

Novartis - Monday - Acquisition - Firm - AveXis

Novartis on Monday announced its $8.7 billion acquisition of gene-therapy firm AveXis, which could add billions in new revenue for the Swiss drugmaker.

The deal is expected to close in the middle of this year, and if it does, it will result in a hefty payday for Dyal Co., a small mergers-and-acquisitions advisory firm that landed the lucrative job of serving as Novartis' banker on the deal. Goldman Sachs and Centerview Partners advised AveXis.

Deal - Fees - Transactions - Tens - Millions

Deal fees for large biotech transactions run into the tens of millions, which isn't chump change for any M&A-advisory firm, let alone a boutique like Dyal, which has roughly 15 employees.

The mandate is yet another coup for Gordon Dyal, the ex-Goldman Sachs rainmaker for whom the small M&A shop is named.

Dyal

So who is Dyal?

Gordon Dyal was a partner at Goldman Sachs for 16 years, rising to the role of co-chairman of the investment banking division in 2011 before retiring from the firm to...
(Excerpt) Read more at: Business Insider
Wake Up To Breaking News!
You can never use the word unexpected when it comes to abuse of power by the government.
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!